

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 00-108

Serial No.
09/995,898

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use separate sheets if necessary)

Applicant(s):

Scott R. Presnell, Wenfeng Xu, Julia E.
Novak, Theodore E. Whitmore, Francis J.
Grant

Filing Date:
November 28, 2001

Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CU	A1	01/02568	01/11/01	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

CU	A2	-	Genuardi, M. et al., Am. Hum. Genet. 45:73-82, 1989.
	A3	.	Ritke, MK et al., Cytogenet. Cell. Genet. 50:84-90, 1989.
	A4		Dracopoli, NC et al., Proc. Nat. Acad. Sci. 86:4614-4618, 1989.
	A5		Wilson, RK. et al., Genbank Database, The WashU-Merck EST Project, 1995: EST522113
	A6		Wei, Y. et al., Genbank Database, Pediatric Leukemia cDNA Sequencing Project, 2000: EST5272157
	A7		Wei, Y. et al., Genbank Database, Pediatric Leukemia cDNA Sequencing Project, 2000: EST5273479
	A8		Incyte Pharmaceuticals, Inc. clone, 1996: INC1274993
	A9		Incyte Pharmaceuticals, Inc. clone, 1996: INC2025095
	A10		TIGR, Tentative Human Consensus, 1997THC_W16444
	A11		Incyte Pharmaceuticals, Inc. clone, 2000: INC7127190H2
	A12		Incyte Pharmaceuticals, Inc. clone, 2000: INC7128744
	A13		Incyte Pharmaceuticals, Inc. clone, 2000: INC8134754
	A14		Incyte Pharmaceuticals, Inc. Library, 1996: TESTTUT02
CU	A15		Incyte Pharmacuticals, Inc. Library, 1996: KERANOT02

Examiner

Date considered

Clayton M. [Signature]

3/31/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.